Adrenergic beta-Antagonists
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
    
			
			
				
				
					
						| Descriptor ID | 
										
							D000319
						 | 			
					
					
						| MeSH Number(s) | 
						
							 D27.505.519.625.050.200.200 D27.505.696.577.050.200.200 
						 | 
					
					
						| Concept/Terms | 
						
							Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
 - Adrenergic beta Antagonists
 - beta-Antagonists, Adrenergic
 - beta-Adrenergic Receptor Blockaders
 - Blockaders, beta-Adrenergic Receptor
 - Receptor Blockaders, beta-Adrenergic
 - beta Adrenergic Receptor Blockaders
 - beta-Adrenergic Blockers
 - Blockers, beta-Adrenergic
 - beta Adrenergic Blockers
 - beta-Blockers, Adrenergic
 - Adrenergic beta-Blockers
 - beta Blockers, Adrenergic
 - Adrenergic beta-Receptor Blockaders
 - Adrenergic beta Receptor Blockaders
 - Blockaders, Adrenergic beta-Receptor
 - beta-Receptor Blockaders, Adrenergic
 - beta-Adrenergic Blocking Agents
 - Agents, beta-Adrenergic Blocking
 - Blocking Agents, beta-Adrenergic
 - beta Adrenergic Blocking Agents
 
  
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2001 | 0 | 1 | 1 | 
| 2005 | 0 | 1 | 1 | 
| 2006 | 1 | 0 | 1 | 
| 2007 | 2 | 1 | 3 | 
| 2008 | 1 | 1 | 2 | 
| 2009 | 0 | 1 | 1 | 
| 2010 | 1 | 0 | 1 | 
| 2011 | 1 | 0 | 1 | 
| 2012 | 3 | 3 | 6 | 
| 2013 | 2 | 1 | 3 | 
| 2014 | 2 | 1 | 3 | 
| 2015 | 0 | 1 | 1 | 
| 2017 | 3 | 1 | 4 | 
| 2018 | 1 | 1 | 2 | 
| 2019 | 1 | 1 | 2 | 
| 2020 | 1 | 0 | 1 | 
| 2022 | 0 | 1 | 1 | 
| 2024 | 1 | 1 | 2 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
						
					
								- 
								
Trends in Initial Antihypertensive Medication Prescribing Among >2.8?Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. J Am Heart Assoc. 2024 Oct 15; 13(20):e036557.
															
								 
							
								- 
								
National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC Heart Fail. 2024 Jun; 12(6):1059-1070.
															
								 
							
								- 
								
Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat. 2022 May; 193(1):225-235.
															
								 
							
								- 
								
ß-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. Am J Kidney Dis. 2021 05; 77(5):704-712.
															
								 
							
								- 
								
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. Am Heart J. 2019 12; 218:57-65.
															
								 
							
								- 
								
Medication-Taking Behaviors and Perceptions Among Adults With Heart Failure (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2019 05 15; 123(10):1667-1674.
															
								 
							
								- 
								
Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich). 2018 11; 20(11):1603-1609.
															
								 
							
								- 
								
Practitioner Gender and Quality of Care in Ambulatory Cardiology Practices: A Report From the National Cardiovascular Data Practice Innovation and Clinical Excellence (PINNACLE) Registry. J Cardiovasc Nurs. 2018 May/Jun; 33(3):255-260.
															
								 
							
								- 
								
Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017 Dec; 65(12):2610-2618.
															
								 
							
								- 
								
ß-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies. JAMA Intern Med. 2017 06 01; 177(6):885-887.